


H K E c a e a d C e a L e d a d T e S c E c a e f H K L e d a e e b
f e c e f a c e e , a e e e e a a a c c a c c e e e a d e e
d c a a a b a e e f a e e a f e a c e e e a a f e
c e f a c e e .



The P e : T e P e ca ed a F 12 15, P a e II, H e
 Ed ca Pa B e Ce e, C a a S bd c, O a
 D c, We C , Z e a P ce, e PRC, a
 f a ea f 4,523.86 . . a da a d e a ea f 267.90
 . . T e a ed e f e P e a d f acc da
 a d ca e / e, a d e e f e a d e
 e e 29 Ja a 2043. T e P e de e ed b G da
 I e e , e e f e e a c a e c f e P e
 G da I e e a cab e.

A a e a bee ce a ed e e P e , S a a
 P d De e e Ba C ., L d. We B a c be e
 a ee. T e a f e e ed a e a be e a ed
 e e f e P e .

A a e da e f a ce e , e P e -
 ed b G da I e e .

De e a d e a f U e C a f a e f e c de a de e
 a fe f e: P e P c a e A ee e , e P e a be de e ed
 e C a a a - ba e eed f a f a
 a d e ced e . G da I e e a a e
 de e e C a e ce f ca e f a d e a d
 b d e , a e a e e c a e ce
 e ec f e P e . T e C a a a de e e a
 f a fe f e f e P e .

W effec f e da e f de e f e P e , a e
 e ce- e a ed e e e a be b e b e C a , a da
 f da a e, a da e a a be b e b
 e C a .

PAYMENT TERMS AND BASIS FOR DETERMINING THE CONSIDERATION

T e a c de a f e ac f e P e RMB31.45 (c e f a).
 T e c de a a de e ed a f e a e e a be ee e a e ba ed e
 fa a e a e, e f e e ce e a a f e P e f RMB35,286,000 c d c ed b
 e de e de e a e , A a- Pac f c C a d A a a L ed (e **Independent**
Valuer), ba ed e a a ed a e a e f e P e a a 30 A 2026 e
 a e c a a ac . T e C a c de e f e f e a a e
 e ec f e P e e c c a f e AGM. T e c a c e f e a a e
 a e a f :

Valuation Date

30 A 2026

Basis of Valuation

The Independent Valuer has carried out a detailed analysis. The value is defined as the fair market value of the shares in the company as at the valuation date. The value is based on the assumption that the shares are freely transferable and that the company is a going concern.

Methods of Valuation

The Independent Valuer has adopted the cost of acquisition method. The value is based on the cost of acquisition of the shares, adjusted for any premium or discount. The value is based on the assumption that the shares are freely transferable and that the company is a going concern.

Valuation Assumptions

The Independent Valuer has made the following assumptions: the company is a going concern; the shares are freely transferable; the value is based on the cost of acquisition of the shares, adjusted for any premium or discount.

The Independent Valuer has also made the following assumptions: the company is a going concern; the shares are freely transferable; the value is based on the cost of acquisition of the shares, adjusted for any premium or discount.

Valuation Standards

In accordance with the Independent Valuer's Code of Ethics, the Independent Valuer has followed the RICS Valuation - Global Standards, the HKIS Valuation Standards, and the IFA Valuation Standards.

Conclusion of Value

The Independent Valuer has concluded that the fair market value of the shares is RMB35,286,000.

In addition, the Independent Valuer has concluded that the fair market value of the shares is RMB90 million, and the fair market value of the shares is RMB407,147.4.

The Independent Valuer has concluded that the fair market value of the shares is RMB9 million, and the fair market value of the shares is 50% of the fair market value of the shares.

T e a c de a f e ac f e P e be f ded b e e a e ce
f e C a .

ONLINE SIGNING

Sa e a d c ed ab e, a a e da e f a ce e , e be ed e a d be ef
 f e D ec a ade a ea ab e e e , S a e de e ed ab a f
 e e e a e a e e P e a Ac a e AGM.

A c c a c a , a e , () f e de a f e P e a Ac ; () a
 e e f e I de e de B a d C ee e I de e de S a e de (e e
 ec e da f e I de e de B a d C ee); () a e e f ad ce f G a Ca a
 e I de e de B a d C ee a d e I de e de S a e de ; () e e a a
 e ; a d () a ce f e AGM, be b ed e eb e f e S c E c a e
 (. e e .) a d e eb e f e C a (. . c), a d d a c ed e
 de f H S a e f e C a acc da ce e c e ea f e ce f c a e
 c ca , c a ce e a cab e L R e .

A add a e e ed f a e ce a f a be c ded e c c a , e
 C a e ec b a d/ d a c e c c a e a e e ab e bef e 9
 J e 2026.

DEFINITIONS

I a ce e , e ec e e e e e , ef e e a a e
 ef ea :

AGM e 2025 a a e e a ee f e C a be c e ed
 d e c e

B a d e b a d f d ec f e C a

C a We Ka H a C ., L d. (溫州康寧醫院股份有限公
 司), a c ed c a e ab ed de e a f
 e PRC, e H S a e f c a e ed e a b a d f e
 S c E c a e (c c de: 2120)

c ec ed e () a e ea a c bed de e L R e

c ec ed a ac () a e ea a c bed de e L R e

D ec () e d ec () f e C a

G da I e e We G da I e e C ., L d. (溫州國大投資有限公司),
 a ed ab c a c a ed e PRC, e a e
 be ef c a e f c M . GUAN We

H S a e () e ea ed f e a e () e a e ca a f e C a
 a a a e f RMB1.00 eac , c a e ed a d ad ed
 e a b a d f e S c E c a e

H K e H K S ec a Ad a e Re f e PRC

I de e de B a d e de e de b a d c ee c a e de e de
 C ee -e ec e D ec (a e , M . ZHONG We a , M . JIN
 L a d M . CHAN Sa Ke H), e ab ed ad e e
 I de e de S a e de e ec f e P e a Ac

I de e de F a c a G a Ca a L ed, a ce ed c a ca e
 Ad e 6 (ad c a e f a ce) e a ed ac de e
 G a Ca a Sec e a d F e O d a ce (C a e 571 f e La f H
 K), a a ed a e I de e de F a c a Ad e ad e
 e I de e de B a d C ee a d e I de e de S a e de
 e ec f e P e a Ac

de e de -e ec e e de e de -e ec e D ec () f e C a
 D ec ()

I de e de S a e de () a e e ed ab a f a e
 S a e de () AGM e ec f e a a f e P e a Ac

L R e e R e G e e L f Sec e T e S c
 E c a e f H K L ed, a a e ded, e e ed
 e e d f e d f e e

e acc d e e e a e a f e We M c a
 G e e f Z e a P ce, e PRC, e a e a d c a e f
 c e c a e e b ec e a d f
 e e e a e e e c b e d b e e e .

PRC C a e Pe e' Re b c f C a, f e e f a ce e ,
 e c de H K , e Maca S ec a Ad a e Re f e
 PRC a d Ta a

P e P c a e e P e P c a e A ee e be e e ed be ee e
 A ee e C a a d G da I e e

P e a Ac e ed c a e f e P e b e C a f G da
 I e e

RMB e a f c e c f e PRC

SFO e Sec e a d F e O d a ce (C a e 571 f e La f
 H K), a a e ded, e e ed e e d f e d f
 e e

S a e () e a e () f e C a , c d d e c S a e () a d H
 S a e ()

S a e de () de () f e S a e ()

S c E c a e T e S c E c a e f H K L ed

. . . a e e e

e P e e e ca ed a F 12 15, P a e II, H e Ed ca
Pa B e Ce e, C a a S bd c, O a D c, We
C, Z e a P ce, e PRC

ea a e() a e ea a c bed de eL R e

B de f e B a d
Wenzhou Kangning Hospital Co., Ltd.
GUAN Weili